Hwei-Chung Wang
Research Subjects
Hwei-Chung Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anne Armstrong
The Christie NHS Foundation Trust, Manchester, United Kingdom
19 shared publications - Cynthia X. Ma
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
19 shared publications - Jacek Jassem
Medical University of Gdansk, Gdansk, Poland
19 shared publications - Katrin Heider
Cancer Research UK Cambridge Institute, University of Cambridge
19 shared publications - Kyung Hae Jung
Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
19 shared publications - Peter Schmid
Queen Mary University of London
19 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
A–C, Best change from baseline in target lesion size (left panels) and DOR (right panels). Left, dotted lines indicate thresholds for partial response (−30%) and progressive disease (20%). One patient who received the oleclumab combination had a CR in their target lesion but experienced progressive disease in a nontarget lesion, with an overall response of progressive disease. *, If the best percentage change from baseline of target lesions was not calculated because of progression, withdrawal, or death, the value was imputed at +20%; , patients with progressive disease as best overall response; #, unconfirmed response. Right, each bar represents an individual patient. Partial response and CR to treatment as well as disease progression are shown as symbols within the colored bars; stable disease is not represented. The length of each bar indicates the duration of treatment. PD-L1 expression was assessed with the VENTANA PD-L1 (SP263) Assay (Roche Diagnostics). Expression was defined as the percentage of the tumor area populated by tumor cells with membranous staining for PD-L1 or immune cells with membranous, cytoplasmic, or punctate PD-L1 staining at any intensity (TAP score). A TAP score ≥10% was considered positive, whereas a TAP score <10% was considered negative. N, no; U, unknown; Y, yes.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
A–C, Best change from baseline in target lesion size (left panels) and DOR (right panels). Left, dotted lines indicate thresholds for partial response (−30%) and progressive disease (20%). One patient who received the oleclumab combination had a CR in their target lesion but experienced progressive disease in a nontarget lesion, with an overall response of progressive disease. *, If the best percentage change from baseline of target lesions was not calculated because of progression, withdrawal, or death, the value was imputed at +20%; , patients with progressive disease as best overall response; #, unconfirmed response. Right, each bar represents an individual patient. Partial response and CR to treatment as well as disease progression are shown as symbols within the colored bars; stable disease is not represented. The length of each bar indicates the duration of treatment. PD-L1 expression was assessed with the VENTANA PD-L1 (SP263) Assay (Roche Diagnostics). Expression was defined as the percentage of the tumor area populated by tumor cells with membranous staining for PD-L1 or immune cells with membranous, cytoplasmic, or punctate PD-L1 staining at any intensity (TAP score). A TAP score ≥10% was considered positive, whereas a TAP score <10% was considered negative. N, no; U, unknown; Y, yes.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Kaplan–Meier plots for overall survival in the intent-to-treat population
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Kaplan–Meier plots for overall survival in the intent-to-treat population
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Most common AEs (≥20% of patients in any arm).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Most common AEs (≥20% of patients in any arm).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Most common AEs (in ≥5% of patients in any arm) possibly related to durvalumab
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Most common AEs (in ≥5% of patients in any arm) possibly related to durvalumab
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Table 2 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Table 2 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Representativeness of study participants
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Representativeness of study participants
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Kaplan–Meier plots for progression-free survival in the intent-to-treat population
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Kaplan–Meier plots for progression-free survival in the intent-to-treat population
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Table 5 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Response and survival outcomes by PD-L1 expression.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 5 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Response and survival outcomes by PD-L1 expression.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Baseline patient demographics and disease characteristics.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Baseline patient demographics and disease characteristics.